Paper Details

  1. Home
  2. Paper Details

Preliminary study of two antiviral agents for hepatitis C genotype 1.

Author: DimitrovaDessislava I, EleyTimothy, EversonGregory T, GardinerDavid F, GhalibReem, GraselaDennis M, GuoTong, LawitzEric, LokAnna S, MartorellClaudia, McPheeFiona, PasquinelliClaudio, PerssonAnna, ReindollarRobert, RustgiVinod, Wind-RotoloMegan, ZhuKurt

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A sustained virologic response was achieved in patients with chronic HCV genotype 1 who had not responded to prior therapy. The combination of daclatasvir and asunaprevir alone or with peginterferon alfa-2a and ribavirin showed promising results.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen. METHODS: This open-label, phase 2a study included an explo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1104430

データ提供：米国国立医学図書館（NLM）

Antiviral Agents for Hepatitis C Genotype 1: A New Frontier

Hepatitis C virus (HCV) infection can lead to liver damage. This phase 2a study investigates the effectiveness of two antiviral agents, daclatasvir and asunaprevir, in treating patients with chronic HCV genotype 1 infection who had not responded to previous therapy.

Daclatasvir and Asunaprevir Show Promise for HCV Treatment

The study found that both daclatasvir and asunaprevir, either alone or in combination with peginterferon alfa-2a and ribavirin, achieved sustained virologic responses in a significant proportion of patients.

Developing More Effective HCV Treatments

This study highlights the potential of direct-acting antiviral agents in treating HCV. Further research is needed to optimize treatment regimens and explore the use of these agents in different patient populations.

Dr. Camel's Conclusion

The battle against HCV is like traversing a treacherous desert. This study, like a beacon of hope, showcases the potential of new antiviral agents to combat this challenging infection. Continued research will guide us to more effective and accessible treatments, helping us conquer the desert of HCV.

Date :
  1. Date Completed 2012-01-27
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

22256805

DOI: Digital Object Identifier

10.1056/NEJMoa1104430

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.